About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Monthly Archives: November 2008
Change Isn’t Over – It Is Just Beginning – Chairmanship of the House Energy and Commerce Committee – Dingell or Waxman?
It has always been a virtual certainty that the outcome of the presidential contest mattered to the pharmaceutical and biotech industries far less than the contests in the Congress. The election last week decided that Democrats were to achieve solid … Continue reading
Posted in Current Affairs
Comments Off on Change Isn’t Over – It Is Just Beginning – Chairmanship of the House Energy and Commerce Committee – Dingell or Waxman?
More Unfinished Business for Obama’s FDA Commissioner
In addition to those qualities listed in Thursday’s post about the FDA Commissioner that Obama must choose, there is also a great deal of unfinished business – principally three things, that the next commissioner must turn attention to pronto. Today’s … Continue reading
Posted in Current Affairs, FDA Policy
2 Comments
Weekly Roundup – 11/07/08
What a week! As I’ve said the past few weeks, change, change, change – not only the way that medical products are approved, but the way they are marketed and who is overseeing the agency that regulates one-fourth of the … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup – 11/07/08
President Obama’s FDA Commissioner
Yesterday Washington DC was an amazing place. Nine out of ten voters had voted for Barack Obama. Everyone was walking around the city with a sort of goofy and dazed expression, myself included. I have never had so many people … Continue reading
Posted in Current Affairs
3 Comments
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma
Cephalon had an approval announcement today that is worth sharing, not only from the clinical point of view, but from a communications point of view. It is an example of a smart announcement and one that demonstrates the growing importance … Continue reading
Posted in Approval Announcements
Comments Off on Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma